肾移植受者血浆氧化三甲胺浓度与全因死亡率的关联
本研究纳入两个前瞻性队列(623例和544例肾移植受者)及315例健康对照,发现血浆TMAO在移植后3个月从29.0 µmol/L显著降至4.5 µmol/L(P < .001),此后保持稳定但仍高于健康对照。在调整分析中,血浆TMAO每升高1个标准差,全因死亡风险独立增加(队列A HR 1.35,95%CI 1.19-1.53;队列B HR 1.34,95%CI 1.23-1.47),提示TMAO与肾移植受者死亡风险相关。
要点
- 肾移植后血浆TMAO在3个月内急剧下降,但未达到健康对照水平。
- 血浆TMAO每升高1-SD,全因死亡风险增加约34%-35%。
- TMAO与肾移植受者全因死亡风险独立相关。
核心结论
- 血浆TMAO在肾移植后急剧下降但未达健康对照水平,较高TMAO与肾移植受者全因死亡风险独立相关。
研究设计与样本
- 前瞻性研究,队列A纳入623例肾移植受者(TransplantLines队列),移植前及移植后3、6、12、24个月评估。
- 队列B纳入544例移植肾功能稳定≥1年的肾移植受者,中位移植后7.4年。
- 315例潜在肾供者作为健康对照,血浆TMAO用质子核磁共振测定。
主要发现
- 血浆TMAO从移植前29.0(IQR 20.6-48.5)µmol/L降至移植后3个月4.5(IQR 2.7-8.6)µmol/L,P < .001。
- 移植后TMAO保持稳定(β -0.4,95%CI -2.2至1.34 µmol/L/年,P = .63),但仍高于健康对照2.6(IQR 1.8-4.3)µmol/L。
- 队列A中位随访2.2年,41例(7%)死亡;TMAO每升高1-SD的全因死亡HR为1.35(95%CI 1.19-1.53),P < .001。
- 队列B中位随访4.1年,78例(14%)死亡;TMAO每升高1-SD的全因死亡HR为1.34(95%CI 1.23-1.47),P < .001。
临床怎么用
- 肾移植受者血浆TMAO在移植后显著下降但仍高于健康人群,提示肠道菌群代谢产物持续暴露。
- 血浆TMAO升高与全因死亡风险增加独立相关,或可作为肾移植受者风险分层参考。
- 需进一步研究改善肠道菌群失调或干预TMAO能否改善肾移植受者临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Trimethylamine N-oxide (TMAO) is a pro-atherosclerotic molecule produced by intestinal microbiome. TMAO has been linked to increased mortality risk in chronic kidney disease, but its effect in kidney transplant recipients (KTR) is unclear. We investigated the pre-post-transplantation plasma TMAO change, and the association of post-transplantation plasma TMAO with all-cause mortality in KTR. METHODS: This prospective study included two cohorts. Cohort A comprised 623 KTR from the TransplantLines Cohort and Biobank Study (ClinicalTrials.gov: NCT03272841), and assessed pre-transplantation and at 3, 6, 12 and 24 months post-transplantation. Cohort B included 544 KTR with a functioning graft for ≥1 year [median 7.4 (3.9-13.0) years post-transplantation] to study late associations. Potential kidney donors (n = 315) served as healthy controls. Plasma TMAO was measured by proton nuclear magnetic resonance. Time-dependent coefficient Cox regression analyses were performed to assess TMAO association with all-cause mortality. RESULTS: Plasma TMAO concentration significantly declined after transplantation {from 29.0 [interquartile range (IQR) 20.6-48.5] µmol/L to 4.5 (IQR 2.7-8.6) mol/L at 3-months post-transplantation, P < .001}. Afterwards it remained stable [β -0.4 (95% confidence interval -2.2 to 1.34) µmol/L per post-transplantation year, P = .63], remaining consistently higher than that of healthy control [2.6 (IQR 1.8-4.3) µmol/L]. In Cohort A, during a median follow-up of 2.2 years, 41 KTR (7%) died. In Cohort B, over a median follow-up of 4.1 years, 78 KTR (14%) died. A 1-SD higher plasma TMAO concentration was independently associated with an increased risk of all-cause mortality in both cohorts [hazard ratio (95% confidence interval) 1.35 (1.19‒1.53); P < .001, and 1.34 (1.23‒1.47); P < .001; respectively]. CONCLUSION: Plasma TMAO decreases sharply after kidney transplantation, without reaching healthy controls levels. A higher plasma TMAO concentration was independently associated with an increased mortality risk in KTR. Further research is warranted to assess whether accounting for gut dysbiosis and TMAO could improve clinical outcomes in KTR.
引用
- Yepes-Calderón M, Martín Del Campo Sanchez F, Kremer D, et al. Plasma trimethylamine N-oxide concentration and all-cause mortality in kidney transplant recipients. Nephrol Dial Transplant. 2025. PMID: 40275497. doi:10.1093/ndt/gfaf071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。